Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.81 +1.5%	$2.66	$1.89 ▼ $4.09	$1.13B	0.62	3.42 million shs	1.95 million shs
AMPH Amphastar Pharmaceuticals	$23.18 -1.7%	$24.73	$22.64 ▼ $53.96	$1.09B	0.72	495,165 shs	221,782 shs
DYN Dyne Therapeutics	$9.05 +1.2%	$11.69	$6.36 ▼ $47.45	$995.72M	1.08	1.82 million shs	1.99 million shs
TKNO Alpha Teknova	$5.22 +2.6%	$5.92	$1.16 ▼ $10.37	$278.43M	0.33	422,842 shs	147,080 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+5.40%	+60.55%	+82.06%	+40.41%
AMPH Amphastar Pharmaceuticals	0.00%	+0.41%	-9.19%	-12.91%	-39.90%
DYN Dyne Therapeutics	0.00%	-5.43%	-35.31%	+9.30%	-73.45%
TKNO Alpha Teknova	0.00%	+2.15%	-9.53%	+11.54%	+331.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.4514 of 5 stars	3.4	1.0	0.0	3.2	3.3	0.0
AMPH Amphastar Pharmaceuticals	4.3633 of 5 stars	3.1	2.0	3.7	1.9	4.2	1.3
DYN Dyne Therapeutics	3.7768 of 5 stars	4.5	3.0	0.0	2.9	3.3	0.0
TKNO Alpha Teknova	3.0699 of 5 stars	3.5	3.0	0.0	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	119.01% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	39.52% Upside
DYN Dyne Therapeutics	3.00	Buy	$41.13	354.42% Upside
TKNO Alpha Teknova	3.00	Buy	$8.50	62.84% Upside

Current Analyst Ratings Breakdown

Latest TKNO, AMPH, DYN, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00
5/29/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$46.00
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	39.39	N/A	N/A	$3.58 per share	1.06
AMPH Amphastar Pharmaceuticals	$731.97M	1.49	$4.99 per share	4.64	$15.23 per share	1.52
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
TKNO Alpha Teknova	$37.74M	7.39	N/A	N/A	$1.55 per share	3.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.40	7.04	6.04	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.48	N/A	N/A	N/A	-60.90%	-28.48%	-19.73%	8/12/2025 (Estimated)

Latest TKNO, AMPH, DYN, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
DYN Dyne Therapeutics	N/A	20.35	20.35
TKNO Alpha Teknova	0.17	5.64	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
AMPH Amphastar Pharmaceuticals	65.09%
DYN Dyne Therapeutics	96.68%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
AMPH Amphastar Pharmaceuticals	27.10%
DYN Dyne Therapeutics	20.77%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.36 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	90.06 million	Optionable
TKNO Alpha Teknova	240	53.44 million	46.76 million	Not Optionable

TKNO, AMPH, DYN, and ABCL Headlines

Recent News About These Companies

Tradewinds LLC. Raises Stock Position in Alpha Teknova, Inc. (NASDAQ:TKNO)

July 6 at 8:48 AM | marketbeat.com

Martha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) Stock

July 2, 2025 | insidertrades.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Director Sells $40,480.00 in Stock

July 1, 2025 | marketbeat.com

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance

June 28, 2025 | ca.finance.yahoo.com

Conestoga Capital Advisors LLC Sells 52,070 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

June 17, 2025 | marketbeat.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

March 6, 2025 | markets.businessinsider.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Alpha Teknova’s Earnings Call: Growth Amid Challenges

March 5, 2025 | tipranks.com

Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript

March 4, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom

TKNO, AMPH, DYN, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.80 +0.06 (+1.47%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$3.78 -0.02 (-0.53%)

As of 07/3/2025 04:57 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.18 -0.41 (-1.72%)

Closing price 07/3/2025 03:50 PM Eastern

Extended Trading

$23.18 0.00 (0.00%)

As of 07/3/2025 04:53 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Dyne Therapeutics NASDAQ:DYN

$9.05 +0.11 (+1.23%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$8.99 -0.06 (-0.62%)

As of 07/3/2025 04:31 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Alpha Teknova NASDAQ:TKNO

$5.22 +0.13 (+2.55%)

As of 07/3/2025 01:19 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time